Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab in Adult Participants With Chronic Pruritus of Unknown Origin (CPUO)
NCT07074977Phase 2Active, not recruiting
- Sponsor
- Galderma
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nemolizumab in chronic pruritus of unknown origin (CPUO), sponsored by Galderma. Started Oct 2025; status: active, not recruiting.
02
Drugs
nemolizumab
03
Conditions
chronic pruritus of unknown origin (CPUO)
Beyond the preview
Go deeper on NCT07074977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07074977.